Transvenous Endocardial Pacing with SelectSecureTM 3830 Lead in Pediatric Patients: Case Series of Two Infants and a Literature Review

Résumé fourni par la source

Abstract Background: The SelectSecureTM 3830 lead is an innovative, lumenless, and thin active fixed lead with a nonretractable screw-in tip and a diameter of 4.1 Fr, making it the thinnest pacing lead available. Its high anti-extrusion properties and durability have shown favorable outcomes in cardiac pacing, especially in pediatric patients. The superfine design and easy implantation of the lead have rendered it a preferred choice in children, particularly in cases of congenital heart disease. Case presentation: This case series presents two infant patients who underwent transvenous endocardial pacing using the SelectSecureTM 3830 lead, along with a comprehensive literature review on the topic. The study followed the patients for 5 years and 1.5 years, respectively, and observed stable pacing parameters, indicating a positive therapeutic outcome and safety. This article discusses the optimal age and body shape for transvenous lead implantation in infants and highlights the advantages and disadvantages of endocardial and epicardial pacing approaches. Although endocardial pacing offers several benefits such as minimal trauma, short hospital stay, and longer battery life, it may not be suitable for intracardiac shunts, and venous occlusion remains a concern. On the other hand, epicardial pacing may be considered for children with challenging endocardial access but comes with higher risk of lead failure and coronary artery compression. This study emphasizes the importance of careful follow-up in pediatric patients with pacing, as lead failure can occur in young patients owing to growth and development, leading to syncope and battery depletion. The article also underscores the significance of selecting the appropriate pacing location to minimize the impact of cardiac function, with right ventricular septal pacing emerging as a preferable option. Conclusions: The SelectSecureTM 3830 lead presents a promising solution for transvenous endocardial pacing in pediatric patients with high atrioventricular block and bradycardia, ensuring safe and effective pacing as they grow and develop.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.